Paragard IUD Removal Complications

The Spectrum of Paragard Removal Complications

Paragard is marketed as a reversible contraceptive that can be removed at any time by a healthcare provider. The removal process is described in the device's prescribing information as involving simple traction on the retrieval strings. In practice, Paragard removal complications range from minor arm fracture requiring hysteroscopic retrieval to life-threatening organ perforation requiring emergency abdominal surgery. Understanding the spectrum of removal complications — and how each level creates legal liability — is critical to evaluating a potential Paragard claim. Complications include: incomplete retrieval with arm fracture, retained fragment with or without symptoms, uterine perforation from retained or migrating fragment, migration to peritoneal cavity and contact with adjacent organs, organ perforation (bowel, bladder, fallopian tube), and hysterectomy as the definitive surgical resolution.

Medical Procedures Used to Address Removal Complications

The surgical escalation pathway for Paragard removal complications follows a predictable progression based on fragment location and degree of migration. Hysteroscopy is the first-line intervention: a thin camera is inserted through the cervix into the uterine cavity under anesthesia, allowing direct visualization and retrieval of fragments within the uterine cavity. When the fragment has penetrated the uterine wall or entered the peritoneum, laparoscopy — three to four small incisions in the abdomen — allows the surgeon to visualize and retrieve the migrated fragment under camera guidance. When the fragment has migrated to or perforated bowel, bladder, or other organs, open laparotomy — a full abdominal incision — may be required for safe organ repair and fragment retrieval. Hysterectomy terminates the escalation when uterine integrity cannot be preserved.

Teva's Duty to Warn About Removal Complications

Central to Paragard litigation is the allegation that Teva's prescribing information — the FDA-approved label that governs what warnings must be given to patients and providers — was inadequate in its description of the risk and severity of removal complications. Plaintiffs argue that the label, while mentioning the possibility of arm breakage, did not quantify the risk, describe the range of surgical interventions that might be required, or give providers sufficient guidance on how to minimize fracture risk during removal. The FDA's MAUDE database contained thousands of reports of removal complications, and Teva's own post-market surveillance should have identified the pattern. Failure to translate that knowledge into updated labeling is the core failure-to-warn theory in MDL 2974.